Novo Nordisk to go slow on Wegovy marketing after getting supply issues in check

Novo Nordisk says it’s gained an upper hand on some of the supply issues that had disrupted last year’s debut of obesity drug Wegovy. However, with demand still uncertain, it’s keeping one eye on supply as it gradually resumes marketing.